Core Viewpoint - XORTX Therapeutics Inc. is actively engaging with the investment community through its participation in the Microcap Conference, where it aims to present its innovative therapies for gout and progressive kidney disease, specifically the XRx-026 and XRx-008 programs [1][2]. Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for progressive kidney disease and gout, with three clinically advanced products: XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-026 for allopurinol intolerant gout, and XRx-101 for acute kidney injury related to COVID-19 [3]. - The company is dedicated to improving the quality of life for patients with kidney disease and gout by targeting purine metabolism and inhibiting uric acid production [3]. Conference Participation - The Microcap Conference, held from January 28 to 30, 2025, in Atlantic City, NJ, provides XORTX with a platform to update investors on its gout program and ADPKD clinical trial preparations [1]. - The CEO of XORTX, Dr. Allen Davidoff, emphasized the importance of one-on-one meetings with potential investors and the opportunity to present the company's plans for FDA marketing approval [2].
XORTX to Present at Microcap Conference